86 related articles for article (PubMed ID: 9066601)
1. pS2 and PAI-1 in ovarian cancer: correlation to pathohistological parameters.
Speiser P; Mayerhofer K; Kucera E; Roch G; Mittelböck M; Gitsch G; Zeillinger R
Anticancer Res; 1997; 17(1B):679-83. PubMed ID: 9066601
[TBL] [Abstract][Full Text] [Related]
2. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
Tong D; Schneeberger C; Czerwenka K; Schmutzler RK; Speiser P; Kucera E; Concin N; Kubista E; Leodolter S; Zeillinger R
Clin Cancer Res; 1999 Jun; 5(6):1497-502. PubMed ID: 10389938
[TBL] [Abstract][Full Text] [Related]
3. pS2 protein status fails to be an independent prognostic factor in an average breast cancer population.
Speiser P; Stolzlechner J; Haider K; Heinzl H; Jakesz R; Pecherstorfer M; Rosen H; Sevelda P; Zeilliger R
Anticancer Res; 1994; 14(5B):2125-30. PubMed ID: 7840511
[TBL] [Abstract][Full Text] [Related]
4. [Cytosolic pS2 levels in 154 non-small-cell lung carcinomas. Correlation with other clinical and biological parameters].
Ruibal A; Núñez MI; del Río MC; García Díez S; Rodríguez J; Alvarez De Linera JA
Rev Esp Med Nucl; 2002 Apr; 21(2):109-14. PubMed ID: 11879619
[TBL] [Abstract][Full Text] [Related]
5. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of the cytosolic content of the pS2 protein in breast cancer].
Tamargo F; Vizoso F; Lamelas ML; Rodil A; Vérez P; Raigoso P; Mulero M; Vázquez J; Roiz C; Allende MT
Rev Esp Med Nucl; 2002 Feb; 21(1):28-33. PubMed ID: 11820999
[TBL] [Abstract][Full Text] [Related]
7. Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity.
Correale M; Paradiso A; Abbate I; Mangia A; Dragone CD; Tedone T; Filotico R; Schittulli F; De Lena M
Tumour Biol; 1993; 14(1):30-7. PubMed ID: 8493448
[TBL] [Abstract][Full Text] [Related]
8. Detection of pS2 messenger RNA in gynecological cancers.
Wysocki SJ; Hahnel E; Masters A; Smith V; McCartney AJ; Hahnel R
Cancer Res; 1990 Mar; 50(6):1800-2. PubMed ID: 2306733
[TBL] [Abstract][Full Text] [Related]
9. Correlation of cytosolic concentrations of ER, PS2, Cath-D, TPS, TK and cAMP in primary breast carcinomas.
Kausitz J; Kuliffay P; Pecen L; Eben K; Puterová B
Neoplasma; 1994; 41(6):331-6. PubMed ID: 7870216
[TBL] [Abstract][Full Text] [Related]
10. Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Hoffmann G; Pollow K; Weikel W; Strittmatter HJ; Bach J; Schaffrath M; Knapstein P; Melchert F; Pollow B
Clin Chem Lab Med; 1999 Jan; 37(1):47-54. PubMed ID: 10094378
[TBL] [Abstract][Full Text] [Related]
11. Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer.
Racca S; Conti G; Pietribiasi F; Stramignoni D; Tampellini M; Valetto MR; Ghezzo F; Di Carlo F
Int J Biol Markers; 1995; 10(2):87-93. PubMed ID: 7561244
[TBL] [Abstract][Full Text] [Related]
12. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
Kuhn W; Schmalfeldt B; Reuning U; Pache L; Berger U; Ulm K; Harbeck N; Späthe K; Dettmar P; Höfler H; Jänicke F; Schmitt M; Graeff H
Br J Cancer; 1999 Apr; 79(11-12):1746-51. PubMed ID: 10206287
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
Grøndahl-Hansen J; Peters HA; van Putten WL; Look MP; Pappot H; Rønne E; Dano K; Klijn JG; Brünner N; Foekens JA
Clin Cancer Res; 1995 Oct; 1(10):1079-87. PubMed ID: 9815897
[TBL] [Abstract][Full Text] [Related]
15. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
Koensgen D; Mustea A; Klaman I; Sun P; Zafrakas M; Lichtenegger W; Denkert C; Dahl E; Sehouli J
Gynecol Oncol; 2007 Nov; 107(2):266-73. PubMed ID: 17698176
[TBL] [Abstract][Full Text] [Related]
16. Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Correlation with prognosis and adjuvant hormone therapy.
Predine J; Spyratos F; Prud'homme JF; Andrieu C; Hacene K; Brunet M; Pallud C; Milgrom E
Cancer; 1992 Apr; 69(8):2116-23. PubMed ID: 1544118
[TBL] [Abstract][Full Text] [Related]
17. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
18. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors.
van der Burg ME; Henzen-Logmans SC; Berns EM; van Putten WL; Klijn JG; Foekens JA
Int J Cancer; 1996 Dec; 69(6):475-9. PubMed ID: 8980250
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer.
Foekens JA; van Putten WL; Portengen H; Rodenburg CJ; Reubi JC; Berns PM; Henzen-Logmans SC; van der Burg ME; Alexieva-Figusch J; Klijn JG
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):815-21. PubMed ID: 2178364
[TBL] [Abstract][Full Text] [Related]
20. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
